Table 4.

Antiviral Activity of 1–3 Against SARS-CoV-2 Variants^a

	1		2		3
variant (replicates)b	EC50 ± SD (μm)	fold change ± SD from WA1c	EC50 ± SD (μm)	fold change ± SD from WA1c	EC50 ± SD (μm)	fold change ± SD from WA1c
WA1 (n = 3)	0.11 ± 0.02	1.0	4.45 ± 1.03	1.0	1.01 ± 0.33	1.0
Delta (B.1.617.2) (n = 3)	0.07 ± 0.04d	0.59 ± 0.20d	3.26 ± 1.30d	0.62 ± 0.24d	0.74 ± 0.38	0.72 ± 0.12
WA1 (n = 7)	0.12 ± 0.03	1.0	6.52 ± 2.01	1.0	1.84 ± 0.35	1.0
Omicron BA.1 (n = 3)	0.04 ± 0.01d	0.45 ± 0.13d	2.66 ± 0.48d	0.37 ± 0.10d	0.65 ± 0.20	0.32 ± 0.04
WA1 (n = 2)	0.11 ± 0.04	1.0	4.55 ± 0.94	1.0	1.92 ± 0.26	1.0
Omicron BA.2 (n = 2)	0.02 ± 0.0002	0.23 ± 0.07	1.33 ± 0.24	0.31 ± 0.12	0.71 ± 0.10	0.37 ± 0.001
WA1 (n = 2)	0.16 ± 0.0006	1.0	7.36 ± 3.46	1.0	1.57 ± 0.21	1.0
Omicron BA.2.12.1 (n = 2)	0.03 ± 0.002e	0.20 ± 0.01e	1.79 ± 0.10	0.28 ± 0.14	0.44 ± 0.13	0.29 ± 0.12
Omicron BA.4 (n = 2)	0.02 ± 0.003	0.15 ± 0.02	1.63 ± 0.28	0.26 ± 0.16	0.40 ± 0.02	0.26 ± 0.02
Omicron BA.5 (n = 2)	0.11 ± 0.003	0.66 ± 0.02	4.80 ± 0.28	0.74 ± 0.39	1.30 ± 0.13	0.83 ± 0.02
WA1 (n = 2)	0.11 ± 0.006	1.0	7.73 ± 0.35	1.0	1.97 ± 0.14	1.0
Omicron BA.2.75 (n = 2)	0.03 ± 0.006	0.30 ± 0.07	2.58 ± 0.72	0.33 ± 0.08	0.69 ± 0.14	0.35 ± 0.05
WA1 (n = 2)	0.15 ± 0.02	1.0	8.56 ± 2.97	1.0	3.96 ± 0.29	1.0
Omicron BA.4.6 (n = 2)	0.09 ± 0.005e	0.64 ± 0.13e	5.40 ± 0.10	0.67 ± 0.25	2.45 ± 0.28	0.62 ± 0.12
Omicron BF.5 (n = 2)	0.13 ± 0.02e	0.94 ± 0.31e	7.78 ± 0.19	0.97 ± 0.36	3.13 ± 0.36	0.80 ± 0.15
WA1 (n = 2)	0.08 ± 0.0004	1.0	6.53 ± 0.58	1.0	1.84 ± 0.14	1.0
Omicron XBB (n = 2)	0.09 ± 0.002	1.07 ± 0.01	6.30 ± 0.97	0.97 ± 0.23	2.03 ± 0.56	1.10 ± 0.22
Omicron BQ.1.1 (n = 2)	0.09 ± 0.002	1.12 ± 0.03	8.77 ± 2.04	1.33 ± 0.18	2.44 ± 0.09	1.33 ± 0.06

^an represents the number of replicate experiments.

^bELISA antiviral assay was assessed at 44 h post-infection for Delta variant and 72 h post-infection for Omicron subvariants.

^cA fold change was calculated for each experiment, and a mean fold change ± SD was calculated with these values.

^dReference 34.

^eReference 35.